Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

Imatinib Mesylate (Gleevec)

300 mg orally twice daily

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER